Moody Lynn Lieberson & Walker LLC Has $42.52 Million Holdings in AbbVie Inc. $ABBV

Moody Lynn Lieberson & Walker LLC trimmed its stake in shares of AbbVie Inc. (NYSE:ABBV) by 4.2% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 168,964 shares of the company’s stock after selling 7,329 shares during the period. AbbVie comprises about 2.2% of Moody Lynn Lieberson & Walker LLC’s portfolio, making the stock its 13th largest position. Moody Lynn Lieberson & Walker LLC’s holdings in AbbVie were worth $42,518,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in ABBV. Litman Gregory Wealth Management LLC bought a new position in AbbVie during the 4th quarter worth about $28,000. Imprint Wealth LLC lifted its holdings in shares of AbbVie by 56.2% in the fourth quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock valued at $29,000 after purchasing an additional 45 shares in the last quarter. Legacy Wealth Managment LLC ID boosted its position in shares of AbbVie by 115.9% during the fourth quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company’s stock worth $31,000 after buying an additional 73 shares during the period. IFC & Insurance Marketing Inc. acquired a new position in shares of AbbVie during the fourth quarter worth about $31,000. Finally, WestEnd Advisors LLC grew its holdings in shares of AbbVie by 160.4% during the fourth quarter. WestEnd Advisors LLC now owns 138 shares of the company’s stock worth $32,000 after buying an additional 85 shares in the last quarter. 70.23% of the stock is owned by institutional investors.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Canada supports UBRELVY reimbursement: Canada’s Drug Agency recommended reimbursement of UBRELVY for acute migraine treatment in adults. The decision could improve access and provide another growth opportunity for AbbVie’s neuroscience portfolio. AbbVie Wins Canada Reimbursement Backing for Adult Migraine Treatment
• Positive Sentiment: BOTOX regulatory progress: AbbVie’s BOTOX filing helped attract investor attention, adding potential support for the aesthetics business and contributing to the stock’s recent strength. AbbVie Gains on Botox Filing
• Positive Sentiment: Immunology remains the key growth engine: Skyrizi and Rinvoq delivered strong sales, market-share gains and contributions from new indications, helping drive AbbVie’s second-quarter growth. Recent results also exceeded consensus estimates for earnings and revenue. How Much Did Immunology Drugs Contribute to AbbVie’s Q2 Performance?
• Neutral Sentiment: Pipeline updates provide optionality but limited immediate impact: AbbVie completed early testing of a venetoclax combination in high-risk myelodysplastic syndromes and completed a Phase 3 BOTOX jawline study. The updates advance development, but the reports did not provide definitive clinical results. AbbVie’s Venetoclax Combo in High-Risk MDS
• Neutral Sentiment: Analyst target increase reflects limited near-term upside: BNP Paribas Exane raised its price target from $218 to $247 while retaining a neutral rating, implying the shares were slightly above its revised valuation. Erste Group also modestly reduced its FY2027 EPS forecast but kept a Buy rating. BNP Paribas Exane AbbVie Price Target
• Negative Sentiment: Apogee acquisition increases leverage: Shareholders approved AbbVie’s Apogee Therapeutics acquisition, expanding the pipeline but requiring roughly $8 billion of additional debt. Investors focused on dividend safety may view the higher leverage and execution risk negatively. AbbVie Piles on $8 Billion in Debt for Its Apogee Deal

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on ABBV shares. Barclays lifted their target price on AbbVie from $275.00 to $300.00 and gave the company an “overweight” rating in a research report on Wednesday, July 29th. Erste Group Bank raised shares of AbbVie from a “hold” rating to a “buy” rating in a research note on Wednesday, August 5th. Cantor Fitzgerald lifted their price objective on shares of AbbVie from $265.00 to $285.00 and gave the company an “overweight” rating in a report on Monday, August 3rd. Wells Fargo & Company boosted their price objective on shares of AbbVie from $260.00 to $295.00 and gave the stock an “overweight” rating in a research report on Friday, July 10th. Finally, UBS Group increased their target price on shares of AbbVie from $230.00 to $260.00 and gave the stock a “neutral” rating in a report on Monday, July 13th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $274.33.

AbbVie Stock Performance

ABBV opened at $249.12 on Thursday. The business’s 50-day simple moving average is $243.99 and its 200 day simple moving average is $225.73. AbbVie Inc. has a 52-week low of $190.75 and a 52-week high of $267.47. The firm has a market capitalization of $440.14 billion, a PE ratio of 70.37, a PEG ratio of 0.83 and a beta of 0.30.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, beating analysts’ consensus estimates of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The firm had revenue of $16.99 billion during the quarter, compared to the consensus estimate of $16.80 billion. During the same period last year, the company earned $2.97 earnings per share. The business’s revenue was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, research analysts forecast that AbbVie Inc. will post 14.07 earnings per share for the current year.

AbbVie Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, August 14th. Investors of record on Wednesday, July 15th will be issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date is Wednesday, July 15th. AbbVie’s payout ratio is presently 195.48%.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.